{"id":1588,"date":"2025-07-23T16:28:48","date_gmt":"2025-07-23T16:28:48","guid":{"rendered":"https:\/\/enfoca.com.mx\/?p=1588"},"modified":"2025-07-23T16:28:50","modified_gmt":"2025-07-23T16:28:50","slug":"tratamientos-anti-vegf-retina","status":"publish","type":"post","link":"https:\/\/enfoca.com.mx\/eng\/tratamientos-anti-vegf-retina\/","title":{"rendered":"Anti &#8211; VEGF UPDATE!"},"content":{"rendered":"<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"SamurA-I #8 Anti VEGF UPDATE\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/Q5Vz180Whf4?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<p>Advances and Challenges in Anti-VEGF Therapies for Retinal Diseases<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">SEO Optimization: Advances and Challenges in Anti-VEGF Therapies for Retinal Diseases<\/h2>\n\n\n\n<p>The <strong>anti-VEGF therapies<\/strong> have transformed the treatment of <strong>retinal diseases<\/strong> like the <strong>neovascular (wet) macular degeneration<\/strong>, he <strong>diabetic macular edema<\/strong> y las <strong>retinal vein occlusions<\/strong>. However, the <strong>frequency of injections<\/strong> and the <strong>burden of treatment for the patient<\/strong> remain key challenges. The primary goal is to maintain vision while minimizing the impact on the patient's life.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Anti-VEGF Treatment Strategies: Balancing Efficacy and Convenience<\/h3>\n\n\n\n<p>There are three main approaches to managing <strong>anti-VEGF therapies<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fixed Dose (FIDO):<\/strong> Offers <strong>solid visual results<\/strong> but it implies a <strong>high treatment load<\/strong> with very frequent injections (approximately 11 per year), which significantly impacts the patient's time and costs.<\/li>\n\n\n\n<li><strong>A Necessity (PRN \u2013 Pro Re Nata):<\/strong> It reduces the number of injections (4 to 8 per year), but carries the risk of undertreatment and possible <strong>long-term vision loss<\/strong> if the disease flares up between visits.<\/li>\n\n\n\n<li><strong>Treat and Extend (TNE \u2013 Treat and Extend):<\/strong> Considering the scheme <strong>favorite<\/strong> According to many specialists, the TNE seeks a balance between <strong>eficacia visual<\/strong> and <strong>lower treatment burden<\/strong>. It begins with frequent injections, and if the eye remains stable, the intervals are gradually extended. This allows for maintaining visual results similar to the fixed dose with fewer injections (8 to 10 per year on average).<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Anti-VEGF Drugs and Future Innovations<\/h3>\n\n\n\n<p>Anti-VEGF Drugs and Future Innovations<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current drugs:<\/strong> <strong>Aflibercept (Aflivers)<\/strong> and <strong>Ranibizumab (Ran Bisumab)<\/strong> They are effective in the TNE scheme, allowing longer intervals. <strong>Bevacizumab (Bebas Isumap)<\/strong> it is a cheaper option used \"off label\", with debates about possible systemic risks.<\/li>\n\n\n\n<li><strong>New drugs:<\/strong> <strong>Brolucizumab (Brulusumap)<\/strong> it promised longer intervals, but raised concerns about intraocular inflammation. <strong>Faricimab (Farisim)<\/strong> it is a promising development that targets two pathways and seeks to extend intervals up to 16 weeks. Higher doses of existing drugs and the entry of <strong>biosimilars<\/strong> that could reduce costs.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">The Burden of Treatment and Patient Adherence<\/h3>\n\n\n\n<p>The <strong>treatment burden<\/strong> goes beyond the injection and includes time, logistics, emotional aspects and dependency. This burden is a key factor in the <strong>low adhesion<\/strong> of the patients, explaining the <strong>gap between clinical trial results and daily practice<\/strong>. Optimal adherence is vital to maintaining long-term vision gains.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">The Future: Fewer Injections, Greater Impact<\/h3>\n\n\n\n<p>The research focuses on <strong>reduce the frequency of treatment<\/strong> without compromising efficacy. Key pathways include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Long-acting drugs:<\/strong> Like Faricimab, looking at intervals of three or four months.<\/li>\n\n\n\n<li><strong>Sustained-release implantable devices:<\/strong> Small reservoirs that release medication continuously for months (e.g. <strong>Sus Bimo<\/strong>), drastically reducing the need for injections, although they do require initial surgery.<\/li>\n\n\n\n<li><strong>Gene therapy:<\/strong> A transformative approach that seeks to have the eye continuously produce the anti-VEGF protein, with the potential for a single-dose treatment that lasts for years.<\/li>\n<\/ul>\n\n\n\n<p>In conclusion, the choice of anti-VEGF strategy should be individualized, seeking <strong>maximize vision and minimize treatment burden<\/strong>. The field is rapidly moving toward less common options, which will improve patient adherence and quality of life.<\/p>\n\n\n\n<p>Are you interested in delving deeper into the <strong>ophthalmology<\/strong>? Find out more <strong>summaries of key topics<\/strong> and <strong>AI-guided reviews<\/strong> to keep you up to date with the <strong>latest advances<\/strong>. Click here!: <a href=\"https:\/\/enfoca.com.mx\/eng\/podcast-samur-ai\/\">https:\/\/enfoca.com.mx\/podcast-samur-ai\/<\/a><\/p>\n\n\n\n<p>If you prefer more dynamic content, explore our <strong>entrevistas exclusivas<\/strong> and <strong>live case analysis<\/strong>, click here!: <a href=\"https:\/\/enfoca.com.mx\/eng\/podcast-samureye\/\">https:\/\/enfoca.com.mx\/podcast-samureye\/<\/a><\/p>\n\n\n\n<p>Don't miss any updates: Follow us on <strong><a href=\"https:\/\/www.instagram.com\/samureyepodcast\/\">Instagram<\/a><\/strong> and <strong><a href=\"https:\/\/www.youtube.com\/channel\/UCMiaTjc7s672UjW4msyA09g\">YouTube<\/a><\/strong> for daily content about <strong>eye health<\/strong> and <strong>eye diseases<\/strong>!<br><br><\/p>\n\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>Avances y Desaf\u00edos en Terapias Anti-VEGF para Enfermedades Retinianas Optimizaci\u00f3n SEO: Avances y Desaf\u00edos en Terapias Anti-VEGF para Enfermedades Retinianas [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":1589,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[9,10],"tags":[137,131,136,139,143,130,128,142,138,141,140,133,14,134,129,20,68,135,132],"class_list":["post-1588","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-podcast","category-samur-a-i","tag-aflibercept","tag-anti-vegf","tag-bevacizumab","tag-brolucizumab","tag-carga-del-paciente","tag-degeneracion-macular","tag-edema-macular-diabetico","tag-enfermedades-de-la-vista","tag-faricimab","tag-implantes-de-liberacion-sostenida","tag-inyecciones-oculares","tag-oclusiones-de-la-vena-retiniana","tag-oftalmologia","tag-ranibizumab","tag-retina","tag-salud-ocular","tag-terapia-genica","tag-tne","tag-treat-and-extend"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anti - VEGF UPDATE! - ENFOCA<\/title>\n<meta name=\"description\" content=\"Descubre los tratamientos anti-VEGF para la degeneraci\u00f3n macular y otras afecciones retinianas. Explora reg\u00edmenes como &quot;Treat-and-Extend&quot;, nuevos f\u00e1rmacos como Faricimab y avances futuros para reducir la carga del paciente.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/enfoca.com.mx\/eng\/tratamientos-anti-vegf-retina\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anti - VEGF UPDATE! - ENFOCA\" \/>\n<meta property=\"og:description\" content=\"Descubre los tratamientos anti-VEGF para la degeneraci\u00f3n macular y otras afecciones retinianas. Explora reg\u00edmenes como &quot;Treat-and-Extend&quot;, nuevos f\u00e1rmacos como Faricimab y avances futuros para reducir la carga del paciente.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/enfoca.com.mx\/eng\/tratamientos-anti-vegf-retina\/\" \/>\n<meta property=\"og:site_name\" content=\"ENFOCA\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-23T16:28:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-23T16:28:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/07\/ANTI-VEGF.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Riquelme\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Riquelme\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/\"},\"author\":{\"name\":\"Riquelme\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/#\\\/schema\\\/person\\\/6a00856a1ddde6dfe3a27187c99d0dad\"},\"headline\":\"Anti &#8211; VEGF UPDATE!\",\"datePublished\":\"2025-07-23T16:28:48+00:00\",\"dateModified\":\"2025-07-23T16:28:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/\"},\"wordCount\":683,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/enfoca.com.mx\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/ANTI-VEGF.png\",\"keywords\":[\"Aflibercept\",\"anti-VEGF\",\"Bevacizumab\",\"Brolucizumab\",\"carga del paciente\",\"degeneraci\u00f3n macular\",\"edema macular diab\u00e9tico\",\"enfermedades de la vista\",\"Faricimab\",\"implantes de liberaci\u00f3n sostenida\",\"inyecciones oculares\",\"oclusiones de la vena retiniana\",\"Oftalmolog\u00eda\",\"Ranibizumab\",\"retina\",\"Salud ocular\",\"Terapia G\u00e9nica\",\"TNE\",\"Treat-and-Extend\"],\"articleSection\":[\"Podcast\",\"Samur A-I\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/\",\"url\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/\",\"name\":\"Anti - VEGF UPDATE! - ENFOCA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/enfoca.com.mx\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/ANTI-VEGF.png\",\"datePublished\":\"2025-07-23T16:28:48+00:00\",\"dateModified\":\"2025-07-23T16:28:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/#\\\/schema\\\/person\\\/6a00856a1ddde6dfe3a27187c99d0dad\"},\"description\":\"Descubre los tratamientos anti-VEGF para la degeneraci\u00f3n macular y otras afecciones retinianas. Explora reg\u00edmenes como \\\"Treat-and-Extend\\\", nuevos f\u00e1rmacos como Faricimab y avances futuros para reducir la carga del paciente.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/#primaryimage\",\"url\":\"https:\\\/\\\/enfoca.com.mx\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/ANTI-VEGF.png\",\"contentUrl\":\"https:\\\/\\\/enfoca.com.mx\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/ANTI-VEGF.png\",\"width\":1920,\"height\":1080,\"caption\":\"Anti VEGF\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/enfoca.com.mx\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anti &#8211; VEGF UPDATE!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/#website\",\"url\":\"https:\\\/\\\/enfoca.com.mx\\\/\",\"name\":\"ENFOCA\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/enfoca.com.mx\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/#\\\/schema\\\/person\\\/6a00856a1ddde6dfe3a27187c99d0dad\",\"name\":\"Riquelme\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g\",\"caption\":\"Riquelme\"},\"url\":\"https:\\\/\\\/enfoca.com.mx\\\/eng\\\/author\\\/drriquelme\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anti - VEGF UPDATE! - ENFOCA","description":"Descubre los tratamientos anti-VEGF para la degeneraci\u00f3n macular y otras afecciones retinianas. Explora reg\u00edmenes como \"Treat-and-Extend\", nuevos f\u00e1rmacos como Faricimab y avances futuros para reducir la carga del paciente.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/enfoca.com.mx\/eng\/tratamientos-anti-vegf-retina\/","og_locale":"en_US","og_type":"article","og_title":"Anti - VEGF UPDATE! - ENFOCA","og_description":"Descubre los tratamientos anti-VEGF para la degeneraci\u00f3n macular y otras afecciones retinianas. Explora reg\u00edmenes como \"Treat-and-Extend\", nuevos f\u00e1rmacos como Faricimab y avances futuros para reducir la carga del paciente.","og_url":"https:\/\/enfoca.com.mx\/eng\/tratamientos-anti-vegf-retina\/","og_site_name":"ENFOCA","article_published_time":"2025-07-23T16:28:48+00:00","article_modified_time":"2025-07-23T16:28:50+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/07\/ANTI-VEGF.png","type":"image\/png"}],"author":"Riquelme","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Riquelme","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/#article","isPartOf":{"@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/"},"author":{"name":"Riquelme","@id":"https:\/\/enfoca.com.mx\/#\/schema\/person\/6a00856a1ddde6dfe3a27187c99d0dad"},"headline":"Anti &#8211; VEGF UPDATE!","datePublished":"2025-07-23T16:28:48+00:00","dateModified":"2025-07-23T16:28:50+00:00","mainEntityOfPage":{"@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/"},"wordCount":683,"commentCount":0,"image":{"@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/#primaryimage"},"thumbnailUrl":"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/07\/ANTI-VEGF.png","keywords":["Aflibercept","anti-VEGF","Bevacizumab","Brolucizumab","carga del paciente","degeneraci\u00f3n macular","edema macular diab\u00e9tico","enfermedades de la vista","Faricimab","implantes de liberaci\u00f3n sostenida","inyecciones oculares","oclusiones de la vena retiniana","Oftalmolog\u00eda","Ranibizumab","retina","Salud ocular","Terapia G\u00e9nica","TNE","Treat-and-Extend"],"articleSection":["Podcast","Samur A-I"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/","url":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/","name":"Anti - VEGF UPDATE! - ENFOCA","isPartOf":{"@id":"https:\/\/enfoca.com.mx\/#website"},"primaryImageOfPage":{"@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/#primaryimage"},"image":{"@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/#primaryimage"},"thumbnailUrl":"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/07\/ANTI-VEGF.png","datePublished":"2025-07-23T16:28:48+00:00","dateModified":"2025-07-23T16:28:50+00:00","author":{"@id":"https:\/\/enfoca.com.mx\/#\/schema\/person\/6a00856a1ddde6dfe3a27187c99d0dad"},"description":"Descubre los tratamientos anti-VEGF para la degeneraci\u00f3n macular y otras afecciones retinianas. Explora reg\u00edmenes como \"Treat-and-Extend\", nuevos f\u00e1rmacos como Faricimab y avances futuros para reducir la carga del paciente.","breadcrumb":{"@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/#primaryimage","url":"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/07\/ANTI-VEGF.png","contentUrl":"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/07\/ANTI-VEGF.png","width":1920,"height":1080,"caption":"Anti VEGF"},{"@type":"BreadcrumbList","@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/enfoca.com.mx\/"},{"@type":"ListItem","position":2,"name":"Anti &#8211; VEGF UPDATE!"}]},{"@type":"WebSite","@id":"https:\/\/enfoca.com.mx\/#website","url":"https:\/\/enfoca.com.mx\/","name":"ENFOCA","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/enfoca.com.mx\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/enfoca.com.mx\/#\/schema\/person\/6a00856a1ddde6dfe3a27187c99d0dad","name":"Riquelme","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g","caption":"Riquelme"},"url":"https:\/\/enfoca.com.mx\/eng\/author\/drriquelme\/"}]}},"_links":{"self":[{"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/posts\/1588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/comments?post=1588"}],"version-history":[{"count":0,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/posts\/1588\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/media\/1589"}],"wp:attachment":[{"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/media?parent=1588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/categories?post=1588"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/tags?post=1588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}